ArticleMedicine2026
DNA methylation-regulated ZDHHC5 and PPT1 in the pathogenesis of osteoporosis.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While osteoporosis (OP) affects over 200 million people globally, the causal roles of protein palmitoylation and its upstream epigenetic regulation in the pathogenesis of the disease remain undefined. We aimed to investigate whether DNA methylation causally influences OP risk by modulating the expression of palmitoylation-related genes. We employed an integrated multi-omics causal inference framework, combining 2-sample Mendelian randomization (MR), summary-data-based MR, Bayesian colocalization, and 2-step mediation MR analyses. Data were sourced from large-scale consortia: the FinnGen study (genome-wide association study: 10,461 cases, 473,264 controls), eQTLGen, GTEx (expression quantitative trait loci), and the GoDMC database (methylation quantitative trait loci). Two-sample MR identified ZDHHC5 as a protective factor (odds ratio = 0.81, 95% confidence interval: 0.76-0.87; P = 6.8 × 10-9) and the depalmitoylase PPT1 as a risk factor (odds ratio = 1.06, 95% confidence interval: 1.03-1.08; P = 7.9 × 10-5) for OP. These findings were corroborated by summary-data-based analysis, and colocalization confirmed a shared causal variant at the ZDHHC5 locus (posterior probability of H4 = 0.947). Mediation analysis revealed that DNA methylation is a central mechanistic link: methylation at site cg13473383 mediated 92.7% of ZDHHC5's protective effect, while sites cg04560534 and cg07033722 mediated 74.8% and 43.4%, respectively, of PPT1's risk effect. This study is the first to establish a causal epigenetic-palmitoylation axis in OP. The genes ZDHHC5 and PPT1, regulated by specific DNA methylation sites, represent novel potential therapeutic targets and biomarkers, offering fresh insights for precision medicine strategies against bone loss.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.